학술논문

Brentuximab vedotin as a single agent in the treatment of a pediatric primary cutaneous CD30+ lymphoproliferative disorder: A case report.
Document Type
Academic Journal
Source
Pediatric Blood & Cancer (PEDIATR BLOOD CANCER), Jun2022; 69(6): 1-3. (3p)
Subject
Language
English
ISSN
1545-5009